Hsbc Holdings PLC Biocryst Pharmaceuticals Inc Transaction History

Hsbc Holdings PLC

$168 Billion
Q3 2024

A detailed history of Hsbc Holdings PLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Hsbc Holdings PLC holds 67,247 shares of BCRX stock, worth $515,784. This represents 0.0% of its overall portfolio holdings.

Number of Shares

67,247

Previous 125,004 46.2%

Holding current value

$515,784

Previous $772,000 33.81%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$6.41 - $8.69 $370,222 - $501,908	-57,757 Reduced 46.2%	67,247 $511,000
Q2 2024 Aug 12, 2024	BUY	$4.13 - $6.79 $127,154 - $209,050	30,788 Added 32.68%	125,004 $772,000
Q1 2024 May 15, 2024	BUY	$4.89 - $7.65 $357,855 - $559,834	73,181 Added 347.9%	94,216 $478,000
Q4 2023 Feb 12, 2024	BUY	$4.98 - $6.77 $10,756 - $14,623	2,160 Added 11.44%	21,035 $125,000
Q3 2023 Nov 13, 2023	BUY	$6.71 - $7.92 $126,651 - $149,490	18,875 New	18,875 $133,000
Q3 2021 Nov 12, 2021	SELL	$14.21 - $17.65 $219,729 - $272,921	-15,463 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$9.5 - $17.24 $146,898 - $266,582	15,463 New	15,463 $244,000
Q1 2021 May 14, 2021	SELL	$7.37 - $13.61 $256,984 - $474,567	-34,869 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$3.37 - $8.61 $40,638 - $103,827	-12,059 Reduced 25.7%	34,869 $259,000
Q3 2020 Nov 12, 2020	SELL	$3.43 - $5.53 $291,014 - $469,187	-84,844 Reduced 64.39%	46,928 $164,000
Q2 2020 Aug 14, 2020	SELL	$1.9 - $5.61 $116,646 - $344,414	-61,393 Reduced 31.78%	131,772 $628,000
Q1 2020 May 15, 2020	BUY	$1.6 - $4.11 $291,507 - $748,809	182,192 Added 1660.37%	193,165 $382,000
Q4 2019 Feb 14, 2020	BUY	$1.59 - $3.45 $17,447 - $37,856	10,973 New	10,973 $38,000

Others Institutions Holding BCRX

# of Institutions

278

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.43B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.

Account

Hsbc Holdings PLC Biocryst Pharmaceuticals Inc Transaction History